Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Odyssey Group Intl Inc
(OP:
ODYY
)
0.0457
-0.0043 (-8.60%)
Streaming Delayed Price
Updated: 2:24 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Odyssey Group Intl Inc
< Previous
1
2
3
Next >
Researchers Develop AI Tool That Scans Retina, Detects Heart Disease in One Minute
October 17, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate
October 14, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Formation of Subsidiary Focused on Treating Neurological Disorders
October 11, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Helmets Will Not Protect Individuals Against Concussions, Expert Says
October 10, 2022
Via
Investor Brand Network
New Study Finds Hypertension Accelerates Bone Aging
September 19, 2022
Via
Investor Brand Network
Ways to Prevent a Child from Choking
August 31, 2022
Via
Investor Brand Network
Research to Examine Potential Link Between Concussions, Long COVID
August 16, 2022
Via
Investor Brand Network
Exposures
COVID-19
Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol
October 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Issues Recap of Concussion Drug Development Program
October 06, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated
October 06, 2022
Via
Investor Brand Network
Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial
October 04, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Dissolves Sports Board, Releases Statement on Drug-Development Program
October 03, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002
September 28, 2022
Via
Investor Brand Network
Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs
September 28, 2022
Via
Investor Brand Network
NFL Reveals That Players Wearing Guardian Caps Reduced Concussion Rates by More than 50%
September 27, 2022
Via
Investor Brand Network
Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses
September 26, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Eyes Intranasal Brain Targeting as Key to Success of PRV-002
September 22, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports Successful Safety Outcomes for Most Recent Phase of Concussion Drug Trial
September 13, 2022
Via
Investor Brand Network
Study Finds That Using Headgear May Reduce Concussion Risk in Lacrosse Players
September 09, 2022
Via
Investor Brand Network
Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage
September 07, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article
August 29, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Poised to Offer First-of-Its-Kind Responsiveness to Concussion
August 26, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product
August 25, 2022
Via
Investor Brand Network
Report Details Most Prevalent Symptoms of Six Cardiovascular Illnesses
August 22, 2022
Via
Investor Brand Network
Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate
August 22, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
August 18, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast
August 16, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Shares Favre Interview
August 11, 2022
Via
Investor Brand Network
Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy
August 11, 2022
Via
Investor Brand Network
Topics
Animal Testing
Exposures
Animal Testing
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial
August 10, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.